Saint Louis, Missouri 63110

  • Cholangiocarcinoma


This is an observational study intended to validate results of a previous study done at the Mayo Clinic. Patients are treated with combination chemotherapy and radiation and maintained on oral Xeloda until they can receive liver transplant. A staging laparotomy is performed before chemoradiation in order to identify patients who will most benefit from the treatment and to improve outcomes.


Inclusion Criteria: 1. Diagnosis of cholangiocarcinoma that has been established preoperatively by at least one of the following criteria: 1. A positive brush cytology or biopsy result obtained at the time of cholangiography; 2. Fluorescence in situ hybridization demonstrating aneuploidy; 3. A serum CA 19-9 value greater than 100 U/mL in the presence of a radiographically characteristic malignant stricture in the absence of cholangitis. 4. Listed for OLT for hilar cholangiocarcinoma 2. Tumor/stricture is above the cystic duct and is unresectable. 3. A suitable candidate for orthotopic liver transplantation as judged by the liver transplant team. All 3 treatment modalities are not needed to confirm eligibility for this registry trial. 4. >/= 18 years of age. 5. Willing and able to provide written informed consent.



Primary Contact:

Principal Investigator
William C. Chapman, M.D.
Washington University School of Medicine

William Chapman, MD
Phone: 314-362-7792

Backup Contact:

Tracey Guthrie
Phone: 314-747-4404

Location Contact:

Saint Louis, Missouri 63110
United States

William Chapman, MD
Phone: 314-362-7792

Site Status: Recruiting

Data Source:

Date Processed: August 03, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.